Showing 2691-2700 of 9152 results for "".
Time Is Hair: An Update on the Diagnosis and Treatment of Scarring Alopecias in Patients with Darker Skin Tones
https://practicaldermatology.com/programs/practical-dermatology/time-is-hair-an-update-on-the-diagnosis-and-treatment-of-scarring-alopecia-in-patients-with-darker-skin-tones/18198/In part two of a three-part podcast series on dermatologic issues facing patients with darker skin tones, Dr. Andrew Alexis, a dermatologist from New York City and the President of the Skin of Color Society; Dr. Corey Hartman, a dermatologist in Birmingham, Alabama; and Dr. Janiene Luke, a dermatoloAdvancing Digital Medicine in Dermatology
https://practicaldermatology.com/programs/practical-dermatology/advancing-digital-medicine-in-dermatology/18187/The Digital Medicine Society (DiME) is a global nonprofit dedicated to advancing the ethical, effective, equitable, and safe use of digital medicine to redefine health care and improve lives. DiME recently released a new set of resources, available at www.dimesociety.org/access-resources/, to advancAddressing the Psychologic Impact of Atopic Dermatitis on Pediatric Patients
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/addressing-the-psychologic-impact-of-atopic-dermatitis-on-pediatric-patients/37174/Elizabeth Lippner, MD, MA, Attending Physician in the Division of Allergy and Immunology and Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine, describes the psychologic impact of atopic dermatitis on children and how clinicians can address these issues.SCALE 2024: Dr. Michael Gold Recaps the Show and Previews 2025
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-michael-gold-recaps-show-and-previews-2025/26751/Michael Gold, MD, FAAD, Course Co-Director for Music City SCALE, discusses the growth of the event over the years, highlights from 2024, and what to expect next year.Skin Biopsy for Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/tbd/48782/James Q. Del Rosso, DO, FAOCD, discusses situations in which histopathology can help to correctly diagnose prurigo nodularis.DWTV Extra: Phase 3 Data on Roflumilast for AD, PsO
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-phase-3-data-on-roflumilast-for-ad-pso/35925/Study investigator Melinda Gooderham, MD, talks about the Phase 3 trials of roflumilast cream 0.15% for adults and children down to age 6 with atopic dermatitis and roflumilast foam 0.3% for patients older than 12 with psoriasis of the scalp and body.Red Light vs Blue Light Therapy
https://practicaldermatology.com/series/pdt-in-practice/red-light-vs-blue-light-therapy/26993/Dr. Hamza D. Bhatti, a board-certified dermatologist and dually accredited fellowship-trained Mohs micrographic surgeon and cosmetic dermatologic surgeon, discusses the differences between red light and blue light photodynamic therapy (PDT), the advantages of each, and some off-label uses of PDT."Best Practices in the Treatment of Acne" Drs. Harper and Stein-Gold
https://practicaldermatology.com/youngmd-connect/ymdc-workshops/best-practices-in-the-treatment-of-acne-drs-harper-and-stein-gold/24543/Expert dermatologists Drs. Linda Stein Gold and Julie Harper share their insights on treating acne across all severities. Join their discussion with YoungMD Connect members for valuable experiences and practice pearls. To access the full video and more, become a YoungMD Connect member for free 90-daA Meeting for Treating the Whole Person
https://practicaldermatology.com/conferences/noah-worcester/a-meeting-for-treating-the-whole-person/57065/Stan Tolkachjov, MD, Scientific Program Co-chair for the Noah Worcester Dermatological Society’s 2026 Annual Meeting, explains what he and Co-chair David Wetter, MD, sought to accomplish with this year’s presentations.DWTV Extra: Rocatinlimab Trials
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-rocatinlimab-trials/39044/Clinical investigator Emma Guttman-Yassky, MD, PhD, discusses two sets of data presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. The phase 3 ROCKET-Ignite Trial evaluated the efficacy and safety of OX40-receptor targeting with rocatinlimab in moderate-to-severe a